Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0)
# 4908
Out of 5,240 analysts
40
Total ratings
11.54%
Success rate
-30.64%
Average return
Main Sectors:
Top Industries:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
Incyte | Reiterates: Neutral | n/a | n/a | n/a | 6 | Jan 10, 2025 | |
Agios Pharmaceutical... | Reiterates: Overweight | n/a | n/a | n/a | 4 | Dec 18, 2024 | |
Tango Therapeutics | Reiterates: Overweight | n/a | n/a | n/a | 3 | Dec 5, 2024 | |
Alumis | Reiterates: Overweight | n/a | n/a | n/a | 3 | Nov 14, 2024 | |
Bicara Therapeutics | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Oct 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 96 96 | 28.52 | 236.61% | 4 | Sep 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | n/a | n/a | n/a | 2 | Sep 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Sep 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Sep 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 292 292 | 145.32 | 100.94% | 3 | Sep 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | n/a | n/a | n/a | 3 | Aug 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | May 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 370 | 419.49 | -11.8% | 1 | Oct 17, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Oct 17, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 31 | n/a | n/a | 1 | Jun 12, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | May 30, 2017 |